Carevive ACCC Business Summit

Carevive made a significant impact at the ACCC Business Summit held in Washington DC. John Elliott, representing Carevive, expressed excitement about being present at the in-person conference and highlighted the organization’s dedication to improving patient outcomes and experiences. Carevive’s partnership with UT-Austin Dell Medical School Cancer Institute was a key focus, promising exciting developments in the coming years.

Partnership Announcement and Future Prospects:

Carevive unveiled its partnership with Care About, generating anticipation and enthusiasm among attendees. The collaboration promises to deliver remarkable advancements in patient care. Tomorrow’s presentation on the evaluation of Carevive’s integrated person volunteer program further piqued interest, and attendees were urged to log into the Life’s platform for future updates.

Sessions and Insights:
The ACCC Business Summit offered a range of sessions focused on enhancing asthma care, utilizing data for improvement, and enhancing the patient experience. Carevive participants eagerly looked forward to Thursday’s session and expressed their commitment to keeping attendees informed in real-time.

Recent Episodes

In this episode of Inside Restoration & Recovery, host Martha Lewis welcomes Jason McClaren, Director of Facilities Operations at Reunion Rehabilitation Hospitals, to discuss the critical advantage of partnering with a restoration team experienced in healthcare. A former firefighter and military veteran, Jason has spent the last decade managing safety, risk, and emergency preparedness…

In this impactful episode of the ConCensis podcast, host Yasmeen Hassan sits down with Robby Miller, Sterile Processing Manager at St. Joseph’s Hospital Medical Center, to explore how artificial intelligence is revolutionizing the field of sterile processing. With nearly 30 years of experience in healthcare, Miller shares his journey from EMT to SPD leader, offering…

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…